Navigation Links
Palatin Technologies Provides Update Regarding Its Obesity Research/Development Collaboration with AstraZeneca
Date:9/7/2012

CRANBURY, N.J., Sept. 7, 2012 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) today announced that its collaboration partner,  AstraZeneca, has decided to discontinue further development of AZD2820, one of a number of collaboration compounds in various stages of development for the treatment of obesity.  AstraZeneca remains committed to this collaboration program and to the continued advancement of melanocortin agonists for treatment of obesity.

AZD2820, a subcutaneously-administered peptide melanocortin-4 receptor partial agonist, was a clinical candidate under development by AstraZeneca from a collaborative research program with Palatin Technologies. As previously announced, a Phase I trial of AZD2820 was halted following a serious adverse event. The decision to discontinue development of the compound was made based on investigations and review conducted by AstraZeneca that followed this incident. While not confirmed, it could not be excluded that the serious adverse event was linked to AZD2820. The investigation further concluded that it is unlikely that the serious adverse event was related to melanocortin receptor activation as an approach for the treatment of obesity.

"We are pleased that the subject has fully recovered from this adverse event," said Dr. Carl Spana, President and Chief Executive Officer of Palatin. "The AZD2820 compound is part of a broader research and development collaboration with AstraZeneca. We have multiple classes of collaboration compounds in various stages of preclinical testing and AstraZeneca has informed us that they remain committed to the advancement of collaboration compounds for treatment of obesity."

Pursuant to the terms of the research collaboration and license agreement with AstraZeneca, Palatin is eligible for milestone payments upon achieving development and regulatory milestones and further payments on achievement of sales targets, in addition to royalties on sales of app
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Palatin Technologies, Inc. To Report Fiscal Year 2012 Fourth Quarter Results; Teleconference and Webcast to be held on September 11, 2012
2. Palatin Technologies, Inc. Announces Pricing of $35 Million Private Placement of Common Stock and Warrants
3. Palatin Technologies Announces Halting of Phase I Clinical Trial of Obesity Compound in AstraZeneca Research Collaboration
4. Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on May 14, 2012
5. Palatin Technologies, Inc. To Report Fiscal Year 2012 Third Quarter Results; Teleconference and Webcast to be held on May 14, 2012
6. Palatin Technologies, Inc. to Present at the 24th Annual ROTH OC Growth Stock Conference
7. Palatin Technologies to Present at Windhovers Therapeutic Area Partnerships Conference
8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
9. Palatin Technologies, Inc. to Report Fiscal Year 2012 First Quarter Results; Teleconference and Webcast to be held on November 15, 2011
10. Lifeline Biotechnologies Receives Patent for Methods to Collect and Analyze Breast Thermal Data to Determine Suspect Conditions
11. Life Technologies to Present at UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... China , 22 juli 2014 BGI ... BGI, ,s wereld grootste organisatie op het gebied van ... service ten behoeve van hele menselijke genoomsequentie via het ... In 2013 acquireerde BGI Complete Genomics, ... staat vanwege de in eigen beheer ontwikkelde sequentietechnologieën met ...
(Date:7/22/2014)... In chemical and petrochemical plants, ... sight. The rapid rise of TDL analyzers over ... as a core gas measurement technology, and their ... the gas analyzer technology of choice for many ... some processes have limited their application range. METTLER ...
(Date:7/22/2014)... Seattle, WA (PRWEB) July 22, 2014 Quorum ... a new service for large clinical trials called Quick ... and is designed to address the research industry’s need for ... The service is available for studies planning 50 or ... with a combined planned North American site count of 80 ...
(Date:7/22/2014)... Juli 2014 Qforma, ein führender Anbieter ... von Marcus Bergler zum General Manager ... europäischen kommerziellen Aktivitäten von Qforma bereits als Vice ... anschloss, war er in Positionen als VP Vertrieb ... Deutschland bei IMS Health und als Direktor bei ...
Breaking Biology Technology:BGI Tech introduceert service op gebied van hele menselijke exoomsequencing op geavanceerd Complete Genomics-platform 2METTLER TOLEDO Shows How Tunable Diode Lasers (TDLs) Can Be Installed Where No TDLs Have Gone Before 2Quorum Review IRB Launches New Quick Step™ Service for Large Clinical Trials 2Quorum Review IRB Launches New Quick Step™ Service for Large Clinical Trials 3Qforma gibt Schaffung des neuen Postens als General Manager in Europa bekannt 2
... Red Herring has announced,that ProGenTech Limited was a winner of the ... technology companies based in Asia. , ... Asia and identified the top 100 out of more than 1,000,closely ... "It is truly an honor ...
... the U.S. Patent and Trademark Office has ... for Traumatic Injury to the Nervous System”, ... University of Florida with the company as ... method of determining the presence of neural ...
... Inc.,(Nasdaq: BNVI ) will present findings on the ... Annual San Antonio Breast Cancer Symposium,being held at the Henry ... Bionovo,s poster presentation will ... BN107. As explained by Dr. Emma Shtivelman,Director of Cancer Research ...
Cached Biology Technology:Red Herring Awards ProGenTech Limited for the 2008 Red Herring Asia 100 2 Banyan Biomarkers Announces Issuance of U.S. Patent for Biomarkers for Traumatic Injury 2Bionovo to Present Recent Findings of BN107, its Anticancer Agent, at the 31st Annual San Antonio Breast Cancer Symposium 2
(Date:7/22/2014)... allergic to dust mites (and chances are you are), ... the University of Iowa have developed a vaccine that ... immune response. In animal tests, the nano-sized vaccine package ... to the allergens, according to the paper, published in ... Journal . One big reason why it works, ...
(Date:7/22/2014)... Health Policy and Economics have linked tighter Medicaid ... for schizophrenic individuals. , The study comes amid ... actually save money, when other costs are taken ... extra approval step before tests or treatments can ... prior authorization is intended to encourage physicians ...
(Date:7/22/2014)... be on the horizon. Bacteria that produce a ... insulin resistance and other adverse effects of a ... discovered., "Of course it,s hard to speculate from ... Ph.D., assistant professor of Pharmacology. "But essentially we,ve ... in mice, even though they,re eating a high-fat ...
Breaking Biology News(10 mins):Researchers create vaccine for dust-mite allergies 2Are state Medicaid policies sentencing people with mental illnesses to prison? 2Vanderbilt study shows therapeutic bacteria prevent obesity in mice 2
... lice treatments such as the pyrethroids cypermethrin and deltamethrin, ... increased from 2008 to 2009, although use of emamectine ... again due to resistance problems, e.g. azametiphos, diflubenzuron and ... 1997, was also used again in 2009, mainly under ...
... The National Foundation for Cancer Research announced today ... the Department of Molecular and Experimental Medicine at The ... of the 5th Annual Szent-Gyrgyi Prize for Progress in ... on a humble chicken virus in the early 1960s, ...
... older than previously thought, says a new analysis of the ... plants, or angiosperms, first arose 140 to 190 million years ... Proceedings of the National Academy of Sciences pushes back ... 25 to 75 million years earlier than either the fossil ...
Cached Biology News:5th Annual Szent-Györgyi Prize for Progress in Cancer Research awarded 25th Annual Szent-Györgyi Prize for Progress in Cancer Research awarded 3Molecular study could push back angiosperm origins 2Molecular study could push back angiosperm origins 3
... is fast emerging as a powerful new ... Until now, only amino groups have been ... reagents such as our Sulfo-SBED. Sulfhydryl-reactive Mts-Atf-Biotin ... exciting additions to the protein interaction tool ...
... is specifically designed as a high tech ... variable mass compensation allows high shaking speed ... aeration and, therefore, faster growth and higher ... ideal when high reproducibility is critical ...
... cocktail of 3 siRNAs specifically targeted to ... popular product. The siTrio reagent guarantees you ... target gene when used under standard conditions ... of optimal transfection with one of B-Bridges ...
... MULTI-FUN Incubator is a compact ... uses a microprocessor controller with a ... temperature and agitation speed. Air circulation ... the incubator. Temperature can be easily ...
Biology Products: